Serono Stops Trials on Two Drugs, Still Depends on Rebif

Serono SA Wednesday said it is terminating trials on two drugs in late development that the Swiss biopharmaceutical company had hoped would reduce its dependence on just one product for growth. Serono said it would stop development of psoriasis drug Onercept and of cancer drug canvaxin. Both drugs were tested on a large number of patients, in the latest development stage before filing them for marketing approval with health authorities.

iWon (http://money.iwon.com/jsp/nw/nwdt_rt.jsp?cat=USMARKET&src=704&feed=dji§ion=news&news_id=dji-00049420050406&date=20050406&alias=/alias/money/cm/nw)